IPOpulse
Back to Ticker

Caplin Point Laboratories Limited

NSE: CAPLIPOINT
Healthcare Healthcare
₹2,258.8
-1.85%EOD · 19 Oct

Caplin Point Laboratories Limited is a listed Healthcare company on NSE/BSE. Detailed profile data is being compiled — check BSE filings for the latest disclosures.

Market Cap
₹17,170 Cr
52W Range
₹2990 / ₹1500
Volume
70K
45.0% delivery
1Y Return
+9.8%
P/E Ratio
26.4
P/B Ratio
5.0
ROE
19.9%
Debt / Equity
0.13

Peers in Healthcare

Top 8 by market cap
CompanyLTP30DMarket CapP/EP/BROE %Div Yld %
Caplin Point Laboratories Limited(this stock)₹2,258.8₹17,170 Cr26.45.019.9%0.35%
Divi's Laboratories LimitedDIVISLAB₹9,087₹2.41 L Cr83.014.516.2%0.33%
Torrent Pharmaceuticals LimitedTORNTPHARM₹4,558.7₹1.73 L Cr72.818.417.0%0.83%
Laurus Labs LimitedLAURUSLABS₹2,069₹1.12 L Cr101.821.017.7%0.12%
Zydus Lifesciences LimitedZYDUSLIFE₹1,113.9₹1.11 L Cr25.04.218.3%0.09%
Apollo Hospitals Enterprise LimitedAPOLLOHOSP₹7,700₹1.11 L Cr54.312.021.5%0.25%
Aurobindo Pharma LimitedAUROPHARMA₹1,621.4₹93,292 Cr26.12.69.9%0.00%
Mankind Pharma LimitedMANKIND₹2,253.2₹93,067 Cr46.05.812.4%0.00%
Max Healthcare Institute LimitedMAXHEALTH₹830₹80,785 Cr56.77.714.3%0.23%

Quality Score

Durability · Valuation · Momentum — objective math, not advice
B
69/100
Composite score: 40% quality, 30% valuation, 30% momentum
QualityStrong · 83
ValuationAverage · 45
MomentumStrong · 75
Low debt (D/E ≤ 0.3)
In confirmed uptrend (Stage 2)

Technical Indicators

Full analysis · objective math, not advice
Returns
1D
-1.8%
1W
-6.7%
1M
-13.0%
3M
-14.7%
6M
+27.6%
1Y
+9.8%
Weinstein Stage
Stage 2 — Advancing (uptrend)
RSI (14)
10 Oversold
Trend Template
5/7moderate
RS vs Nifty (3M)
-8.9pp
Moving Averages (price vs MA)
20-DMA
₹2595
below
50-DMA
₹2608
below
150-DMA
₹2269
below
200-DMA
₹2144
above
From 52W High
-24.5%
From 52W Low
+50.6%
Support (20D)
₹2248
Resistance (20D)
₹2990

Technical indicators are objective calculations from historical EOD prices (RSI, moving averages, Weinstein stage, Minervini trend-template, relative strength). For educational reference only — not a buy/sell recommendation.

Community discussion(0)

Sign in to join the discussion.

Sign in

No comments yet — be the first to share your view.